Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

Programmed death 1 (PD-1) pathway inhibitors have not been prospectively evaluated in patients with non–clear cell renal cell carcinoma (nccRCC). The phase II KEYNOTE-427 study (cohort B) was conducted to assess the efficacy and safety of single-agent pembrolizumab, a PD-1 inhibitor, in advanced ncc...

Descripción completa

Detalles Bibliográficos
Autores principales: McDermott, David F., Lee, Jae-Lyun, Ziobro, Marek, Suarez, Cristina, Langiewicz, Przemyslaw, Matveev, Vsevolod Borisovich, Wiechno, Pawel, Gafanov, Rustem Airatovich, Tomczak, Piotr, Pouliot, Frederic, Donskov, Frede, Alekseev, Boris Yakovlevich, Shin, Sang Joon, Bjarnason, Georg A., Castellano, Daniel, Silverman, Rachel Kloss, Perini, Rodolfo F., Schloss, Charles, Atkins, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078262/
https://www.ncbi.nlm.nih.gov/pubmed/33529058
http://dx.doi.org/10.1200/JCO.20.02365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078262/
https://www.ncbi.nlm.nih.gov/pubmed/33529058
http://dx.doi.org/10.1200/JCO.20.02365

Ejemplares similares